The Indian Health Service continues to work closely with our tribal partners to coordinate a comprehensive public health response to COVID-19. Read the latest info.
Diabetes Standards of Care and Resources for Clinicians and Educators
Aspirin and Other Antiplatelet Therapy
Antiplatelet therapy, including aspirin and clopidogrel, may be used to reduce the risk of cardiovascular disease (CVD) events in appropriate patients with diabetes.
Recommendations for Aspirin and Other Antiplatelet Therapy
Secondary Prevention
Patients with a history of Atherosclerotic Cardiovascular Disease (ASCVD)* should receive aspirin 75-162mg who are not at increased risk of bleeding.
If allergic to aspirin, consider clopidogrel 75mg daily.
Primary Prevention
Consider aspirin 75-162mg in patients with increased risk of ASCVD, (e.g., age ≥ 50 years and one or more risk factors**), who are not at increased risk of bleeding.
Aspirin is not recommended in patients at lower risk of ASCVD, (e.g., age < 50 years with no other major ASCVD risk factors**).
* ASCVD is atherosclerosis affecting the vasculature of any of the following: the heart, periphery (e.g., legs, carotids), and the brain (e.g., stroke, transient ischemic attack).
** Risk factors include: family history of premature ASCVD, hypertension, dyslipidemia, smoking, or albuminuria.
Clinician and Educator Resources
Featured Aspirin and Other Antiplatelet Therapy Resources
